Yahoo
OTC Markets OTCPK - Delayed Quote USD

EV Biologics, Inc. (YECO)

0.0004 0.0000 (0.00%)
At close: November 6 at 4:00:00 PM EST
Chart Range Bar
Loading chart for YECO
  • Previous Close 0.0004
  • Open 0.0191
  • Bid 0.0018 x 1000000
  • Ask 0.0560 x 3350500
  • Day's Range 0.0191 - 0.0191
  • 52 Week Range 0.0001 - 0.1056
  • Volume 10,000
  • Avg. Volume 820
  • Market Cap (intraday) 4,090
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 0.00
  • EPS (TTM) 0.6000
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est --
  • Moby Rating Neutral

EV Biologics, Inc., a biotechnology company, engages in the commercial development of extracellular vesicles (EVs) as biological modalities for diagnostics and therapeutics. It is involved in developing vaccines, therapeutics, and cures based on its proprietary multifunctional EV platform. The company also focuses on developing human mesenchymal and other stem cell, and cell-derived products to market in the cosmetic and biopharmaceutical spaces. The company was formerly known as Yulong Eco-Materials Limited and changed its name to EV Biologics, Inc. in August 2020. EV Biologics, Inc. was incorporated in 2011 and is headquartered in Cheyenne, Wyoming.

www.evbiologics.com

284

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

YECO
99.51%
S&P 500 (^GSPC)
7.76%

1-Year Return

YECO
99.60%
S&P 500 (^GSPC)
9.77%

3-Year Return

YECO
99.97%
S&P 500 (^GSPC)
68.96%

5-Year Return

YECO
99.98%
S&P 500 (^GSPC)
57.04%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -5.82%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    9.47M

  • Net Income Avi to Common (ttm)

    -551.58k

  • Diluted EPS (ttm)

    0.6000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.81M

  • Total Debt/Equity (mrq)

    318.53%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: